Smith, Moore & Co. Precigen, Inc. Transaction History
Smith, Moore & Co.
- $1.03 Billion
- Q3 2024
A detailed history of Smith, Moore & Co. transactions in Precigen, Inc. stock. As of the latest transaction made, Smith, Moore & Co. holds 15,000 shares of PGEN stock, worth $11,400. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,000Holding current value
$11,400% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PGEN
# of Institutions
143Shares Held
159MCall Options Held
232KPut Options Held
69K-
Third Security, LLC83.5MShares$63.4 Million73.5% of portfolio
-
Patient Capital Management, LLC Baltimore, MD17.9MShares$13.6 Million0.92% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA10.9MShares$8.26 Million0.02% of portfolio
-
Black Rock Inc. New York, NY10.2MShares$7.79 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.33MShares$6.33 Million0.0% of portfolio
About PRECIGEN, INC.
- Ticker PGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 208,150,000
- Market Cap $158M
- Description
- Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...